A detailed history of Los Angeles Capital Management LLC transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 105,370 shares of KOD stock, worth $558,461. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,370
Previous 119,129 11.55%
Holding current value
$558,461
Previous $279,000 1.43%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$2.2 - $3.25 $30,269 - $44,716
-13,759 Reduced 11.55%
105,370 $275,000
Q2 2024

Aug 05, 2024

SELL
$2.29 - $4.48 $30,686 - $60,032
-13,400 Reduced 10.11%
119,129 $279,000
Q1 2024

Apr 05, 2024

SELL
$3.01 - $7.45 $64,925 - $160,696
-21,570 Reduced 14.0%
132,529 $697,000
Q3 2023

Nov 06, 2023

SELL
$1.8 - $7.49 $594 - $2,471
-330 Reduced 0.21%
154,099 $277,000
Q2 2023

Aug 03, 2023

BUY
$4.3 - $9.48 $16,555 - $36,498
3,850 Added 2.56%
154,429 $1.07 Million
Q1 2023

May 04, 2023

SELL
$4.81 - $8.88 $12,799 - $23,629
-2,661 Reduced 1.74%
150,579 $933,000
Q4 2022

Feb 06, 2023

BUY
$6.52 - $8.05 $241,989 - $298,775
37,115 Added 31.96%
153,240 $1.1 Million
Q3 2022

Nov 02, 2022

BUY
$7.57 - $12.5 $404,200 - $667,437
53,395 Added 85.12%
116,125 $899,000
Q2 2022

Aug 05, 2022

BUY
$5.04 - $9.48 $316,159 - $594,680
62,730 New
62,730 $479,000
Q4 2021

Feb 03, 2022

SELL
$80.85 - $128.49 $257,588 - $409,369
-3,186 Closed
0 $0
Q3 2021

Nov 08, 2021

SELL
$81.97 - $106.94 $307,715 - $401,452
-3,754 Reduced 54.09%
3,186 $306,000
Q2 2021

Aug 05, 2021

SELL
$77.2 - $126.54 $30,880 - $50,616
-400 Reduced 5.45%
6,940 $645,000
Q1 2021

May 05, 2021

BUY
$110.45 - $164.47 $33,135 - $49,341
300 Added 4.26%
7,340 $832,000
Q4 2020

Feb 04, 2021

BUY
$60.78 - $154.03 $96,336 - $244,137
1,585 Added 29.06%
7,040 $1.03 Million
Q2 2020

Aug 05, 2020

BUY
$42.74 - $66.25 $233,146 - $361,393
5,455 New
5,455 $295,000

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $276M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.